Merck & Co., Inc. (MRK) Gains FDA Priority Review for KEYTRUDA Regimen in Muscle-Invasive Bladder Cancer

On: April 24, 2026, 3:34 pm EDT

URL has been copied successfully!

Share this story:

Previous Post:Jefferies Sees International Business Machines Corporation (IBM) Upside, Trims Price Target on Valuation Ahead of Earnings

Next Post:The Procter & Gamble Company (PG) Price Target Reduced to $167 by BofA Amid Higher Resin Cost Expectations